Related Experiment Video

Updated: Dec 21, 2025

Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma
10:21

Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma

Published on: September 20, 2024

674

Cathepsin S: investigating an old player in lung disease pathogenesis, comorbidities, and potential therapeutics

Ryan Brown1, Sridesh Nath2, Alnardo Lora2

  • 1Airway Innate Immunity Research (AiiR) Group, Wellcome-Wolfson Institute for Experimental Medicine, School of Medicine, Dentistry and Biomedical Sciences, Queen's University Belfast, Belfast, Northern Ireland, UK.

Respiratory Research
|May 14, 2020
PubMed

Insights

Cathepsin S (CTSS) dysregulation contributes to lung diseases and related conditions like cancer. Inhibiting CTSS shows promise as a therapeutic strategy for these pulmonary diseases.

Area of Science:

  • Biochemistry
  • Immunology
  • Pulmonology

Background:

  • Cathepsin S (CTSS), a lysosomal protease, is implicated in lung disease pathogenesis.
  • CTSS exhibits elastase activity and regulates inflammation by processing cytokines and host defense proteins.
  • CTSS activity is linked to pulmonary disease comorbidities, including cancer, cardiovascular disease, and diabetes.

Purpose of the Study:

  • To review the role of CTSS signaling in pulmonary diseases and associated comorbidities.
  • To discuss CTSS as a potential therapeutic target.
  • To summarize current clinical trials investigating CTSS inhibition.

Main Methods:

  • Literature review of CTSS function in pulmonary diseases.
  • Analysis of CTSS involvement in inflammation and antigen presentation.
  • Examination of clinical trial data for CTSS inhibitors.

Main Results:

  • Dysregulated CTSS expression and activity are associated with various lung conditions.
  • CTSS plays a role in inflammation, immune responses, and disease comorbidities.
  • CTSS inhibition is being explored as a therapeutic approach.

Conclusions:

  • CTSS is a significant factor in pulmonary disease development and progression.
  • Targeting CTSS offers a promising therapeutic avenue for lung diseases and comorbidities.
  • Ongoing clinical trials are evaluating the efficacy of CTSS inhibitors.

More Related Videos

Monitoring Neutrophil Elastase and Cathepsin G Activity in Human Sputum Samples09:23

Monitoring Neutrophil Elastase and Cathepsin G Activity in Human Sputum Samples

Published on: May 21, 2021

17.9K
Generation of Human 3D Lung Tissue Cultures 3D-LTCs for Disease Modeling05:47

Generation of Human 3D Lung Tissue Cultures 3D-LTCs for Disease Modeling

Published on: February 12, 2019

21.8K

Related Concept Videos

Chronic Obstructive Pulmonary Disease-II: Pathophysiology01:20

Chronic Obstructive Pulmonary Disease-II: Pathophysiology

Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation
4.0K
COPD: Pathogenesis and Clinical Features01:20

COPD: Pathogenesis and Clinical Features

Chronic obstructive pulmonary disease (COPD) is a group of lung conditions that progressively worsen over time, including chronic bronchitis and emphysema. This cluster of diseases collectively leads to a gradual and irreversible decline in lung function over time.
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
1.7K
Pulmonary Hypertension: Classification and Pathogenesis01:30

Pulmonary Hypertension: Classification and Pathogenesis

Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...
489
Cystic Fibrosis: Management01:24

Cystic Fibrosis: Management

Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic...
373
Cystic Fibrosis: Pathogenesis01:23

Cystic Fibrosis: Pathogenesis

Cystic fibrosis (CF), an autosomal recessive disorder, significantly affects the function of exocrine glands. This genetically inherited disease is characterized by the production of thick and sticky mucus, which can severely affect various organs and systems in the body.
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation,...
644
Asthma: Pathogenesis and Management01:20

Asthma: Pathogenesis and Management

Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
1.1K